GlassScriptPhysician profile
Veronica Hurst Cammack
NPI 1144367533
$1,597.62
in general payments reported to CMS, 2019-2025
22 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $25.78 · 2021: $149 · 2022: $321 · 2023: $328 · 2024: $403 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $277.59 | 2021-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $151.49 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $149.67 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $130.70 | 2019-2024 | |
| Corium, LLC | $108.06 | 2021-2023 | Azstarys |
| Sanofi Pasteur INC. | $106.07 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.43 | 2019-2022 | |
| Glaxosmithkline, LLC. | $101.27 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Astrazeneca Pharmaceuticals LP | $67.61 | 2023-2024 | Flumist Quadrivalent, Tagrisso |
| Seqirus USA INC | $66.34 | 2024-2025 | Flucelvax |
| Collegium Pharmaceutical, INC. | $51.73 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $48.16 | 2024-2025 | Doc Band |
| Sobi, INC | $41.43 | 2021-2023 | |
| Tris Pharma INC | $35.23 | 2022-2023 | Dyanavel Xr |
| Rhodes Pharmaceuticals L.P. | $33.15 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28.04 | 2019 | |
| Cipher Pharmaceuticals US LLC | $19.04 | 2025 | Spinosad, Natroba |
| Alexion Pharmaceuticals, INC. | $18.08 | 2022 | |
| Neurelis, INC. | $17.35 | 2021 | |
| Abbott Laboratories | $16.03 | 2024 | Id Now Instrument |
| Ironwood Pharmaceuticals, INC | $13.89 | 2024 | |
| Dermira, INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Cammack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.